Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) – Stock analysts at William Blair lowered their Q3 2023 earnings per share estimates for Charles River Laboratories International in a research note issued to investors on Friday, September 22nd. William Blair analyst M. Smock now forecasts that the medical research company will post earnings of $2.34 per share for the quarter, down from their previous forecast of $2.37. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.51 per share. William Blair also issued estimates for Charles River Laboratories International’s Q2 2024 earnings at $2.68 EPS.
Other equities research analysts also recently issued reports about the company. Guggenheim dropped their target price on Charles River Laboratories International from $255.00 to $225.00 and set a “buy” rating on the stock in a report on Friday. Bank of America dropped their target price on Charles River Laboratories International from $245.00 to $230.00 in a report on Friday. Robert W. Baird dropped their target price on Charles River Laboratories International from $267.00 to $256.00 and set an “outperform” rating on the stock in a report on Friday. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Finally, Wells Fargo & Company dropped their target price on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating on the stock in a report on Friday. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $237.36.
Charles River Laboratories International Trading Up 0.7 %
Charles River Laboratories International stock opened at $199.62 on Monday. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. The business’s fifty day simple moving average is $205.79 and its two-hundred day simple moving average is $201.95. Charles River Laboratories International has a 12 month low of $181.22 and a 12 month high of $262.00. The company has a market capitalization of $10.23 billion, a price-to-earnings ratio of 21.17, a price-to-earnings-growth ratio of 1.78 and a beta of 1.33.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.06. Charles River Laboratories International had a return on equity of 18.99% and a net margin of 11.58%. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company posted $2.77 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis.
Institutional Trading of Charles River Laboratories International
Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 1.1% during the first quarter. Vanguard Group Inc. now owns 5,935,727 shares of the medical research company’s stock valued at $1,685,568,000 after purchasing an additional 66,602 shares during the period. BlackRock Inc. grew its holdings in Charles River Laboratories International by 8.6% during the second quarter. BlackRock Inc. now owns 5,198,037 shares of the medical research company’s stock valued at $1,092,887,000 after purchasing an additional 411,153 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Charles River Laboratories International by 35.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock valued at $505,821,000 after purchasing an additional 653,790 shares during the period. State Street Corp grew its holdings in Charles River Laboratories International by 1.8% during the second quarter. State Street Corp now owns 2,091,017 shares of the medical research company’s stock valued at $439,636,000 after purchasing an additional 37,816 shares during the period. Finally, Clearbridge Investments LLC grew its holdings in Charles River Laboratories International by 24.4% during the second quarter. Clearbridge Investments LLC now owns 1,750,110 shares of the medical research company’s stock valued at $367,961,000 after purchasing an additional 343,076 shares during the period. Institutional investors own 98.91% of the company’s stock.
Insider Transactions at Charles River Laboratories International
In other news, Director Richard F. Wallman acquired 1,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $198,790. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Richard F. Wallman acquired 1,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $198,790. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 700 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the sale, the executive vice president now owns 24,983 shares of the company’s stock, valued at approximately $5,409,319.16. The disclosure for this sale can be found here. Insiders sold 7,934 shares of company stock worth $1,722,048 over the last quarter. 1.30% of the stock is currently owned by insiders.
About Charles River Laboratories International
Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- What Are Dividend Achievers? An Introduction
- 3 Reasons This Sleeping Giant Is About To Wake Up
- What is the S&P/TSX Index?
- MarketBeat Week in Review – 9/18 – 9/22
- What are stock market earnings reports?
- 52-week Low Names To Tip The Upside Scale In Your Favor
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
